This Article Full Text Full Text (PDF) All Versions of this Article: 90/6/3688    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wright, J. W. Articles by Rodland, K. D. Search for Related Content PubMed PubMed Citation Articles by Wright, J. W. Articles by Rodland, K. D. Related Collections Female Endocrinology

High-Dose Estrogen and Clinical Selective Estrogen Receptor Modulators Induce Growth Arrest, p21, and p53 in Primate Ovarian Surface Epithelial Cells

Division of Reproductive Sciences (J.W.W., R.L.S.), Oregon National Primate Research Center, Beaverton, Oregon 97006; Department of Physiology and Pharmacology (R.L.S.), Oregon Health Sciences University, Portland, Oregon 97201; and Molecular BioSciences Department (K.D.R.), Pacific Northwest National Laboratory, Richland, Washington 99352

Address all correspondence and requests for reprints to: Jay Wright, Division of Reproductive Sciences, Oregon Regional Primate Research Center, Beaverton, Oregon 97006. E-mail: wrightj{at}ohsu.edu.

Ovarian cancer is the most lethal gynecological cancer affecting women. Hormone-based therapies are variably successful in treating ovarian cancer, but the reasoning behind these therapies is paradoxical. Clinical reagents such as tamoxifen are considered to inhibit or reverse tumor growth by competitive inhibition of the estrogen receptor (ER); however, high-dose estrogen is as clinically effective as tamoxifen, and it is unlikely that estrogen is acting by blocking ER activity; however, it may be activating a unique function of the ER that is nonmitogenic. For poorly defined reasons, 90% of ovarian cancers derive from the ovarian surface epithelium (OSE). In vivo the ER-positive OSE is exposed to high estrogen levels, reaching micromolar concentrations in dominant ovarian follicles. Using cultured rhesus OSE cells in vitro, we show that these levels of estradiol (1 µg/ml; 3 µM) block the actions of serum growth factors, activate the G₁ phase retinoblastoma checkpoint, and induce p21, an inhibitor of kinases that normally inactivate the retinoblastoma checkpoint. We also show that estradiol increases p53 levels, which may contribute to p21 induction. Supporting the hypothesis that clinical selective ER modulators activate this novel ER function, we find that micromolar doses of tamoxifen and the "pure antiestrogen" ICI 182,780 elicit the same effects as estradiol. We propose that, in the context of proliferation, these data clarify some paradoxical aspects of hormone-based therapy and suggest that a fuller understanding of normal ER function is necessary to improve therapeutic strategies that target the ER.

This article has been cited by other articles:

				J. W. Wright, T. Pejovic, J. Fanton, and R. L. Stouffer Induction of proliferation in the primate ovarian surface epithelium in vivo Hum. Reprod., January 1, 2008; 23(1): 129 - 138. [Abstract] [Full Text] [PDF]

				P. C.K. Leung and J.-H. Choi Endocrine signaling in ovarian surface epithelium and cancer Hum. Reprod. Update, March 1, 2007; 13(2): 143 - 162. [Abstract] [Full Text] [PDF]

				V. Vijayanathan, S. Venkiteswaran, S. K. Nair, A. Verma, T.J. Thomas, B. T. Zhu, and T. Thomas Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2038 - 2048. [Abstract] [Full Text] [PDF]

				J. L. Tarry-Adkins, S. E. Ozanne, A. Norden, H. Cherif, and C. N. Hales Lower antioxidant capacity and elevated p53 and p21 may be a link between gender disparity in renal telomere shortening, albuminuria, and longevity Am J Physiol Renal Physiol, February 1, 2006; 290(2): F509 - F516. [Abstract] [Full Text] [PDF]